Clearmind Medicine and SciSparc Ltd. publish patent application for Ketamine-based combination treatments.

Clearmind Medicine and SciSparc Ltd. announced the publication of a patent application for innovative Ketamine-based combination treatments under the international Patent Cooperation Treaty. Their collaboration focuses on combining SciSparc's PEA and Clearmind's MEAI to treat addictions, promote weight loss, and address mental health disorders. To date, 13 patents related to this collaboration have been filed.

August 29, 2024
589 Articles

Further Reading